ImmunGene is a Thousand Oaks, CA-based biotechnology company developing antibody-cytokine fusion technology therapies to treat cancer. Its lead approach focuses on antibody-interferon fusion constructs that aim to target interferon to tumor cells and reduce interferon-related dose-limiting toxicity. The company recently received U.S. and international patents, including US 8,258,263 and US 8,563,692 covering the antibody-interferon fusion technology, and US 8,497,354 covering a fully human monoclonal antibody that targets multiple human tumors. ImmunGene will use the $9m in milestone-based Series A financing to advance its early-stage development products to IND-enabling studies. Sanjay D. Khare, PhD, serves as President and CEO. The company has strengthened its board and advisory ranks to support near-term preclinical and regulatory objectives.

Total raised

$9M

Funding rounds

1

Latest round

Series A

Latest activity

Nov 2013